Shots:

• The P-III HEIGHT study involves assessing of Transcon Growth Hormone (hGH) n=105 vs Pfizer’s Genotropin (n=56) in 161 children with GHD in ratio 2:1
• The P-III HEIGHT study resulting in meeting its 1EPs- non-inferior/superior to Pfizer’s Genotropin- annualized height velocity (AHV) @52 wks. (11.2 cm/yr. vs 10.3 cm/yr.)- AEs (1% vs 1.8%)- safe & tolerable and presented at ENDO on 24 Mar-2019
• Transcon hGH (0.24 mg/kg/wk.- SC- qw-) is a long acting hGH therapy used to overcome the burden of daily injection on patients with its expected BLA submission in FDA in H1’20

Ref: Ascendis Pharma | Image: Cape Business News